The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
APOE4 homozygosity represents a distinct genetic form of Alzheimer’s disease
Open accessAbstract
This study aimed to evaluate the impact of APOE4 homozygosity on Alzheimer's disease (AD) by examining its clinical, pathological and biomarker changes to see whether APOE4 homozygotes constitute a distinct, genetically determined form of AD. Data from the National Alzheimer's Coordinating Center and five large cohorts with AD biomarkers were analyzed. The analysis included 3,297 individuals for the pathological study and 10,039 for the clinical study. Findings revealed that almost all APOE4 homozygotes exhibited AD pathology and had significantly higher levels of AD biomarkers from age 55 compared to APOE3 homozygotes. By age 65, nearly all had abnormal amyloid levels in cerebrospinal fluid, and 75% had positive amyloid scans, with the prevalence of these markers increasing with age, indicating near-full penetrance of AD biology in APOE4 homozygotes. The age of symptom onset was earlier in APOE4 homozygotes at 65.1, with a narrower 95% prediction interval than APOE3 homozygotes. The predictability of symptom onset and the sequence of biomarker changes in APOE4 homozygotes mirrored those in autosomal dominant AD and Down syndrome. However, in the dementia stage, there were no differences in amyloid or tau positron emission tomography across haplotypes, despite earlier clinical and biomarker changes. The study concludes that APOE4 homozygotes represent a genetic form of AD, suggesting the need for individualized prevention strategies, clinical trials and treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“APOE is a lipoprotein involved in the transport of cholesterol and phospholipids between cells, and allelic variation in the APOE gene is a strong genetic risk factor for AD [16, 44].”
From Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome–Alzheimer’s disease (2025) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“The isoform variation of the protein is associated with an increased risk of developing AD in the general population [11, 16, 44].”
From Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome–Alzheimer’s disease (2025) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“APOE4 is the strongest genetic risk factor for AD not only increasing the odds ratio of developing the disease but also lowering the age of onset in a dose-dependent fashion.17, 18”
From ApoE is Secreted as a Lipid Nanoparticle by Mammalian Cells: Implications for Alzheimer’s Disease Pathogenesis (2025) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“APOE4 is the strongest genetic risk factor for AD not only increasing the odds ratio of developing the disease but also lowering the age of onset in a dose-dependent fashion.17, 18”
From ApoE is Secreted as a Lipid Nanoparticle by Mammalian Cells: Implications for Alzheimer’s Disease Pathogenesis (2025) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“APOE4 is the strongest genetic risk factor for AD not only increasing the odds ratio of developing the disease but also lowering the age of onset in a dose-dependent fashion.17, 18”
From ApoE is Secreted as a Lipid Nanoparticle by Mammalian Cells: Implications for Alzheimer’s Disease Pathogenesis (2025) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Although APOEε4 homozygosity may approach 100% penetrance for Aβ deposition in the brain16, even for white or East Asian people, being homozygous for APOEε4 is not synonymous with developing AD dementia”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [16]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“APOE is a lipoprotein involved in the transport of cholesterol and phospholipids between cells, and allelic variation in the APOE gene is a strong genetic risk factor for AD [16, 44].”
From Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome–Alzheimer’s disease (2025) · cites this paper as [16]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationThe Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citationMontine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894
New insights into the genetic etiology of Alzheimer’s disease and related dementias
Bellenguez, C., Küçükali, F., Jansen, I. E., Kleineidam, L., Moreno-Grau, S., Amin, N., Naj, A. C., Campos-Martin, R., Grenier-Boley, B., Andrade, V., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01024-z · Cited by 2,498
Self-citationPrevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610
Self-citationLaMontagne, P. J., Benzinger, T. L., Morris, J. C., Keefe, S., Hornbeck, R., Xiong, C., Grant, E., Hassenstab, J., Moulder, K., Vlassenko, A. G., et al. (2019) · medRxiv · doi:10.1101/2019.12.13.19014902 · Cited by 779
The A4 Study: Stopping AD Before Symptoms Begin?
Sperling, R. A., Rentz, D. M., Johnson, K. A., Karlawish, J. H., Donohue, M., Salmon, D. P., & Aisen, P. S. S. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007941 · Cited by 778
Self-citationAPOE and Alzheimer disease: a major gene with semi-dominant inheritance
Genin, E., Hannequin, D., Wallon, D., Sleegers, K., Hiltunen, M., Combarros, O., Bullido, M. J., Engelborghs, S., De Deyn, P., Berr, C., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.52 · Cited by 714
Research works printed but not linked: 1
- Johnson, S. C. et al. The Wisconsin Registry for Alzheimer’s Prevention: a review of findings and current directions. Alzheimer’s Dement.: Diagnosis, Assess. Dis. Monit. 10, 130–142 (2018).
Cited by
Sorted by citations
Items 301–368 of 368
Benjamin, S. R., Dutra, R. F., & de Andrade, G. M. (2026) · Springer eBooks · doi:10.1007/978-3-031-52641-1_38-2
Faucher, C., Thienel, R., Behler, A., Gómez, L., Fripp, J., Breakspear, M. J., & Lupton, M. K. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261427707
Rodríguez‐Baz, Í., Vaqué‐Alcázar, L., Maure‐Blesa, L., Pertierra, L., Arranz, J., Molina‐Porcel, L., Aldecoa, I., Ferreira, N. V., Paradela, R. S., Videla, L., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9044264/v1
Self-citationStewart, P., & Boscarino, J. J. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261431359
The role of the α7 nicotinic acetylcholine receptor in a model of amyloid pathology
Santos, D. G. (2024) · theses.fr (ABES) · doi:10.70675/b3ed4de5zcd9ez4421za129z0a05130d86b9
Ugwah-Oguejiofor, C. J., Okechukwu, P. N., Mathias, S. N., Ofokansi, M. N., & Janakiraman, A. K. (2026) · Studies in natural products chemistry · doi:10.1016/b978-0-443-49144-3.00007-1
Basche, K. E., He, D., Langhough, R. E., Jonaitis, E., Du, L., Bruno, D., Wilson, R., Hermann, B., Johnson, S. C., & Mueller, K. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261446477
Self-citationGuen, Y. L., Park, J. Y., Peña‐Tauber, A., & Greicius, M. D. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71688
Schulten, W., Czaniera, N. J., Fazel, M., Kaltschmidt, B., & Kaltschmidt, C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104325
Sánchez‐Valle, R., Alcolea, D. A., Ferrer, G. A., Balasa, M., Naranjo, I. C., Fortea, J., Lladó, A., Lleó, A., Montes, A. M., Lozano, L. M., et al. (2026) · Neurología · doi:10.1016/j.nrl.2026.502075
Self-citationAPOE Gene Editing as a Therapeutic Target Toward Precision Medicine in AD
Teter, B., Campagna, J. J., Spilman, P., & John, V. (2026) · Springer eBooks · doi:10.1007/978-3-031-96089-5_73
Neuroinflammation- molecular target based therapeutic approach
Paul, D. (2026) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2026.04.006
ApoE and COVID-19 Risk and Long-Term Burden
Tavares-Júnior, J. W. L., Ciurleo, G. C. V., Oriá, R. B., & Braga‐Neto, P. (2026) · Springer eBooks · doi:10.1007/978-3-031-96089-5_56
Mahley, R. W. (2026) · Springer eBooks · doi:10.1007/978-3-031-96089-5_2
Brain tau network derived biomarker improves the diagnostic accuracy of Alzheimer’s disease
Pan, T., Zhou, Q., Li, P., Nie, B., Li, N., Yang, H., Shan, B., & Li, W. (2026) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2026.111962
Sánchez‐Valle, R., Alcolea, D. A., Ferrer, G. A., Balasa, M., Naranjo, I. C., Fortea, J., Lladó, A., Lleó, A., Montes, Á. M., Lozano, L. M., et al. (2026) · Neurología (English Edition) · doi:10.1016/j.nrleng.2026.502075
Self-citationKhan, F. F., & Kwon, G. (2026) · Biomedicines · doi:10.3390/biomedicines14061280
Age-Related Speech-in-Noise Hearing Loss in Parkinson’s Disease and APOE E4 CarriersPreprint
Kmiecik, M. J., Xu, W., Weldon, C. H., Guan, A. S., McIntyre, M. H., Bouchard, E. L., Schneider, R. B., Auton, A., & Aslibekyan, S. W. (2026) · medRxiv · doi:10.64898/2026.06.08.26355175
APOE 4 genotype, blood-brain barrier leakage, ischaemic stroke subtype and locationPreprint
Laing, K. K., Hernández, M. D. C. V., Thrippleton, M. J., Thrippleton, M. J., Makin, S., Chappell, F. M., Dando, O., Vasoya, D., Armitage, P. A., & Wardlaw, J. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.05.730537
Yang, N. V., Hodgson, D., Jang, T. M., Kim, J., Gottschalk, W. K., Yassine, H. N., Chiba‐Falek, O., & Krauss, R. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.09.731195
Pietilä, E. M., Mira, K., Helin, S., Snellman, A., Matti, V., Antti, J., Rinne, J. O., & Ekblad, L. L. (2026) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2026.06.004
Chan, B., Wong, S. T. C., & Qi, S. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1015702
Gomar, J. J., Gordon, M. L., Christen, E., Giliberto, L., Keehlisen, L., Gong, M., Hoehn, N., Morley, E., O'Neil, A., Wuelfing, D. L., et al. (2026) · medRxiv · doi:10.64898/2026.06.18.26355956
Wei, T., Wang, Y., Zhang, L., Wang, X., Xu, Y., Wu, N., Zhao, Y., Li, J., & Tu, Y. (2026) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c17743
Song, J.-A., Yun, T., & Ha, J. (2026) · The Journal of Korean Institute of Information Technology · doi:10.14801/jkiit.2026.24.6.61
Subtyping and staging of Alzheimer’s disease from routine structural MRI with PHASE–ADPreprint
Baumeister, H., Lüsebrink, F., Kleineidam, L., Hansen, N., Schmid, M., Moscoso, A., Leuzy, A., Mastenbroek, S. E., Groot, C., Brosseron, F., et al. (2026) · medRxiv · doi:10.64898/2026.06.26.26356678
Jordan, D. M., Kritzer, E., Thompson, R. C., Lund, A. N., Patel, T., Grice, A. B., John, D., Initiative, A. D. N., Initiative, A. D. N., Goate, A., et al. (2026) · medRxiv · doi:10.64898/2026.07.07.26356710
The past, present, and future of Alzheimer's disease—part 3: the future
Nitríni, R., Takada, L. T., & Brucki, S. M. D. (2026) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0046-1824435
Du, Y., Li, S., Wen, Y., Du, B., & Jiang, G. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1843523
The human retina in Alzheimer’s disease: Pathology, mechanisms, and biomarkers
Müller, L. P. D. S., Majumdar, S., & Recio, B. S. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103275
Wang, J. Y., & Ansorage, O. (2026) · BMC Women s Health · doi:10.1186/s12905-026-04712-8
Recht, M., Finke, K., Gruber, M., Forstner, A. J., Goltermann, J., Richter, M., Straube, B., Schrammen, E., Rau, M., Repple, J., et al. (2026) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2026.101321
Novel Plasma Proteins Associated With Alzheimer’s Disease Risk in APOE ε4 Carriers and Non-carriersPreprint
Leng, Y., Ding, H., Yang, J., Liu, X., Lu, A., Tao, Q., Ma, J., Gifford, K. A., Ang, T. F. A., Qiu, W. Q., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10359931/v1
Karan, K. R., Hackett, N. R., & Crystal, R. G. (2026) · Human Gene Therapy · doi:10.1177/10430342261473427 · Cited by 1
Lee, S., Munoz-Oreja, M., Villar-Fernandez, M., Goicoechea-Barrenechea, L., Fernandez-Pelayo, U., Perez-Rodriguez, D., Gegg, M., de Arbina, A. L., Spinazzola, A., & Holt, I. J. (2026) · doi:10.64898/2026.08.04.742391
Toward personalized medicine in AD/ADRD through genetic-exposome dementia risk assessments
Tolosa‐Tort, P., Okorie, M., Chatterjee, A., Boeriu, A. I., Sharma, R. U., & Andrews, S. J. (2026) · npj Dementia · doi:10.1038/s44400-026-00087-7
Human Stem Cell-Derived Models of the Alzheimer’s Disease Neuroimmune System
Summers, R., Quang, D., & Johnson, N. R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167360 · Cited by 1
AI-aided neuroimaging for the diagnosis of Alzheimer's disease: A concise review of recent studies
Lee, Y., Nadalin, P., Onemli, E., Hadad, R., Yu, F., Greenbaum, L., Greenbaum, A., & Ahn, J. (2026) · Heliyon · doi:10.1016/j.heliyon.2026.e45308
Challenges in Studying Synapses in Alzheimer's Disease
Südhof, T. C. (2026) · Annals of Neurology · doi:10.1002/ana.78331
Towards a future without dementia
Spires‐Jones, T. L. (2026) · Oxford University Press eBooks · doi:10.1093/9780198995296.003.0008
Hey, J. A., Geerts, H., Schaefer, J. F., Short, S. M., van der Graaf, P. H., Abushakra, S. R., Power, A., Tolar, M., & Yu, Y. (2026) · Research Square · doi:10.21203/rs.3.rs-10570608/v1
Controversies in dementia research
Spires‐Jones, T. L. (2026) · Oxford University Press eBooks · doi:10.1093/9780198995296.003.0007
The neuroscience of Alzheimer’s disease
Spires‐Jones, T. L. (2026) · Oxford University Press eBooks · doi:10.1093/9780198995296.003.0003
Akhter, F., Akhter, A., Zhou, J., Xi, M., & Zhu, D. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2026.08.054
Clinical correlates of APOE ε4 homozygosity in Alzheimer’s dementia: findings from an Indian cohort
Vinod, P., Arampady, C., Sen, S., Janardhanan, M., Kota, L. N., Ganesh, S., Jayasankar, P., Shankarappa, B. M., Paul, P., Nayok, S. B., et al. (2026) · Neurodegenerative Disease Management · doi:10.1080/17582024.2026.2723525
Hey, J. A., Abushakra, S. R., Power, A., Watson, D., Porsteinsson, A. P., Sabbagh, M., MacSweeney, E., Cohen, S., Boada, M., Doraiswamy, P. M., et al. (2026) · Drugs · doi:10.1007/s40265-026-02381-3
Molecular programs in human locus coeruleus link APOE and neuromelanin to Alzheimer’s vulnerability
Mulvey, B., Divecha, H. R., Tippani, M., Bach, S. V., Bharadwaj, R. A., Rosario, I. D., Maguire, S. E., Miller, R. A., Salisbury, A. J., Chandra, A., et al. (2026) · Acta Neuropathologica · doi:10.1007/s00401-026-03073-8 · Cited by 1
Vecino, R., Díaz‐Guerra, E., Arribas-González, E., Gil, D. S., Acosta, F. J. F., Serra, I., Moreno‐Jiménez, E. P., Moratalla, R., Navarrete, M., & Vicario‐Abejón, C. (2026) · Research Square · doi:10.21203/rs.3.rs-10968101/v1
Wang, H.-J., Liu, L., Li, Y.-H., Qiu, Y.-H., Xia, X., Cai, Y., & Zhang, S.-J. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1805467
Eshghi, M., Rong, P., Dadgostar, M., Shin, H., Richburg, B. D., Barnett, N. V., Salat, D. H., Arnold, S. E., & Green, J. R. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1740391 · Cited by 5
Moreno, M. D. M. M., Celis, K., Rajabli, F., Whitehead, P. L., Hamilton‐Nelson, K. L., Dykxhoorn, D. M., Nuytemans, K., Mesulam, M. M., Bennett, D. A., Schuck, T., et al. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1888862
Li, Y., Zhang, M., Ying, C., Han, C., Li, Q., & Cai, Y. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1727449
Wenhua, Y., Wenjing, M., Yan, D., Fei, L., Chen, J., Xia, T., Guan, Y., Xin, L., Huang, Y., Guo, Y., et al. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1934307
Emerging therapeutic strategies to target APOE4 in Alzheimer's disease
Jiang, W. I., 王冰莹, & Ma, D. K. (2026) · FEBS Journal · doi:10.1111/febs.70759
Shrirame, D., Tatode, A., Dabhade, D., Taksande, J., Taksande, B. G., Kakade, O., & Umekar, M. (2026) · Physiology & Behavior · doi:10.1016/j.physbeh.2026.115522
Mugikura, S., Mori, N., Satake, M., Chiba, I., Taira, M., Koyama, T., Onuma, T., Saito, T., Takase, M., Motoike, I. N., et al. (2026) · Neuroradiology · doi:10.1007/s00234-026-04210-6
Zhang, J., Zhou, H., Sun, F., Yang, P., Li, K., 管春香, He, J., Zhong, Z., Sun, S., Wu, Q., et al. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-03291-3
Clinical utility of plasma APOE proteotyping for Alzheimer’s disease risk and prognosisPreprint
Shi, R., Choity, L. T., Farinas, M. F., Zeng, X., Emanuel, J. E., Saeed, A., Reís, S. E., López, O. L., Kamboh, M. I., Cohen, A. D., et al. (2026) · medRxiv · doi:10.64898/2026.10.08.26364972 · Cited by 1
Apolipoprotein A (ApoA) in Cardiovascular Disorders: Connections and Insights
Hassanein, A., Rajha, H. E., Hamid, M. A., Hashem, I. E.-A., Al-Saady, R., & Pedersen, S. (2026) · Angiology · doi:10.1177/00033197261491118
Allele-specific GNB3 modulation of APOE ε4 memory effects
Ling-Yi, X., Su, Y.-D., Lin, C.-Y., Hsu, H.-C., & Hsueh, P.-R. (2026) · Scientific Reports · doi:10.1038/s41598-026-63878-1
Barberà-Parada, S., Biosca-Brull, J., Gabaldón-Díaz, R., Rodulfo-Cárdenas, R., Guardia-Escote, L., Blanco, J., Cabré, M., & Colomina, M. T. (2026) · Behavioural Brain Research · doi:10.1016/j.bbr.2026.116524
Multiple target strategies in Alzheimer’s disease therapy
Ma, X., Sun, H., & Ye, J. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.10.018
Shi, H., Zhao, Y., Wei, Z., Yan-jiang, W., & Bu, X.-L. (2026) · Trends in Neurosciences · doi:10.1016/j.tins.2026.09.009
APOE ε4 accelerates plasma p-tau217 trajectory: a Bayesian joint longitudinal analysis of ADNI
Chu, K.-Y. (2026) · Neurological Sciences · doi:10.1007/s10072-026-09435-0
Shateri, A. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261499713
Hou, T., Wei, Q., Shi, L., liu, C., Zhu, M., Tian, X., Zhang, H., Tian, N., Liu, K., González‐Ortiz, F., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-11220681/v1
Mitochondrial dysfunction in neurology: biomarkers and clinical implications
Rossini, E., Garibaldi, M., Hanna, M. G., Pitceathly, R. D. S., & Pizzamiglio, C. (2026) · Nature Reviews Neurology · doi:10.1038/s41582-026-01274-z
Cavallaro, N. J., Maheswari, A., Chukwuemeka, T., Koganov, A., Sundararaj, N., D'Argenio, S., Stotland, H., Weiss, D., Botelho, G., Kulkarni, P. P., et al. (2026) · Genes Brain & Behavior · doi:10.1111/gbb.70076
Metadata
- Authors
- Fortea, J., Pegueroles, J., Alcolea, D., Belbin, O., Dols-Icardo, O., Vaqué-Alcázar, L., Videla, L., Gispert, J. D., Suárez-Calvet, M., Johnson, S. C., Sperling, R., Bejanin, A., Lleó, A., & Montal, V.
- Affiliations
- Hospital de Sant Pau (ES)
- Universitat Pompeu Fabra (ES)
- University of Wisconsin–Madison (US)
- Brigham and Women's Hospital (US)
- Barcelona Supercomputing Center (ES)
- Corresponding author
- Fortea, Juan
- Montal, Víctor
- ORCID
- Venue
- Nature Medicine
- Published
- 2024-05
- Volume
- 30
- Issue
- 5
- Pages
- 1284-1291
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC13310155
- OpenAlex
- W4396673676
- Cited by
- 369
- References
- 32
- Citations by year
- 2026: 110 · 2025: 191 · 2024: 67
- FWCI
- 104.73
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-06-17)
- Open access
- Licence
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Funders
- U.S. Department of Health and Human Services (U54HD090256, P01AG036694 and P50AG005134, R21 AG056974, R01 AG027161, S10 OD025245, UF1AG051216, P50 AG033514, and P30 AG062715, UL1 TR002373, P30 AG062715, R01 AG061566, R01 AG054059, R01 AG037639)
- Alzheimer's Association (AARG-22-923680)
- European Commission (948677 and 847648, H2020-SC1-BHC-2018-2020, Grant 2021)
- Generalitat de Catalunya (SLT006/17/00119, SLT002/16/00408)
- Ministerio de Economía y Competitividad (PI22/00307, PI20/01330, PI20/01473, PI18/00435, PI22/00456)
- Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona (LCF/PR/GN17/50300004)
- National Institutes of Health (5u01ag024904-10, 1s10od025245-01, UL1TR002373)
- National Institute on Aging (U01-AG-024904, R01AG081394, UF1AG051216, RF1AG056850, R61AG066543, R01AG037639, R01AG063689, P50AG033514, RF1AG061566, P50AG005134, R21AG056974, R01AG021155, R01AG027161, U24AG057437, P01AG036694, R01AG054059, P30AG062715, U24AG072122)
- National Center for Advancing Translational Sciences
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54HD090256)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- Alzheimer's disease, APOE3, amyloid PET, cerebrospinal fluid amyloid, tau PET, symptom onset age, disease progression, autosomal dominant Alzheimer's disease, Down syndrome, penetrance, dementia stages
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Apolipoproteins E, Female, Homozygote, Humans, Male, Middle Aged, Cohort Studies, Biomarkers, Amyloid beta-Peptides, tau Proteins, Age of Onset, Positron-Emission Tomography, Apolipoprotein E3, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
